An FDA-Validated, Self-Cleaning Liquid Chromatography-Mass Spectrometry System for Determining Small-Molecule Drugs and Metabolites in Organoid/Organ-on-Chip Medium
Language English Country United States Media print-electronic
Document type Journal Article, Validation Study, Research Support, Non-U.S. Gov't
PubMed
38985547
PubMed Central
PMC11270525
DOI
10.1021/acs.analchem.4c02246
Knihovny.cz E-resources
- MeSH
- Chromatography, Liquid methods MeSH
- Solid Phase Extraction MeSH
- Mass Spectrometry methods MeSH
- Liver * metabolism MeSH
- Liquid Chromatography-Mass Spectrometry MeSH
- Small Molecule Libraries analysis metabolism chemistry MeSH
- Lab-On-A-Chip Devices MeSH
- Pharmaceutical Preparations metabolism analysis MeSH
- Humans MeSH
- Organoids * metabolism cytology MeSH
- Tolbutamide metabolism analysis MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Validation Study MeSH
- Names of Substances
- Small Molecule Libraries MeSH
- Pharmaceutical Preparations MeSH
- Tolbutamide MeSH
As organoids and organ-on-chip (OoC) systems move toward preclinical and clinical applications, there is an increased need for method validation. Using a liquid chromatography-mass spectrometry (LC-MS)-based approach, we developed a method for measuring small-molecule drugs and metabolites in the cell medium directly sampled from liver organoids/OoC systems. The LC-MS setup was coupled to an automatic filtration and filter flush system with online solid-phase extraction (SPE), allowing for robust and automated sample cleanup/analysis. For the matrix, rich in, e.g., protein, salts, and amino acids, no preinjection sample preparation steps (protein precipitation, SPE, etc.) were necessary. The approach was demonstrated with tolbutamide and its liver metabolite, 4-hydroxytolbutamide (4HT). The method was validated for analysis of cell media of human stem cell-derived liver organoids cultured in static conditions and on a microfluidic platform according to Food and Drug Administration (FDA) guidelines with regards to selectivity, matrix effects, accuracy, precision, etc. The system allows for hundreds of injections without replacing chromatography hardware. In summary, drug/metabolite analysis of organoids/OoCs can be performed robustly with minimal sample preparation.
See more in PubMed
Zhao Z.; Chen X.; Dowbaj A. M.; Sljukic A.; Bratlie K.; Lin L.; Fong E. L. S.; Balachander G. M.; Chen Z.; Soragni A.; Huch M.; Zeng Y. A.; Wang Q.; Yu H. Organoids. Nat. Rev. Methods Primers 2022, 2, 94.10.1038/s43586-022-00174-y. PubMed DOI PMC
Leung C. M.; de Haan P.; Ronaldson-Bouchard K.; Kim G.-A.; Ko J.; Rho H. S.; Chen Z.; Habibovic P.; Jeon N. L.; Takayama S.; Shuler M. L.; Vunjak-Novakovic G.; Frey O.; Verpoorte E.; Toh Y.-C. A guide to the organ-on-a-chip. Nat. Rev. Methods Primers 2022, 2, 33.10.1038/s43586-022-00118-6. DOI
Vandana J. J.; Manrique C.; Lacko L. A.; Chen S. Human pluripotent-stem-cell-derived organoids for drug discovery and evaluation. Cell Stem Cell 2023, 30, 571–591. 10.1016/j.stem.2023.04.011. PubMed DOI PMC
Shoji J.; Davis R. P.; Mummery C. L.; Krauss S. Global Meta-Analysis of Organoid and Organ-on-Chip Research. Adv. Healthcare Mater. 2023, 2301067.10.1002/adhm.202301067. PubMed DOI
FDA . No Longer Needs to Require Animal Tests before Human Drug Trials; Science. https://www.science.org/content/article/fda-no-longer-needs-require-animal-tests-human-drug-trials.
Ingber D. E. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat. Rev. Genet. 2022, 23, 467–491. 10.1038/s41576-022-00466-9. PubMed DOI PMC
Kogler S.; Kømurcu K. S.; Olsen C.; Shoji J.; Skottvoll F. S.; Krauss S.; Wilson S. R.; Røberg-Larsen H. Organoids, organ-on-a-chip, separation science and mass spectrometry: An update. TrAC, Trends Anal. Chem. 2023, 161, 116996.10.1016/j.trac.2023.116996. DOI
Olsen C.; Wang C.; Aizenshtadt A.; Abadpour S.; Lundanes E.; Skottvoll F. S.; Golovin A.; Busek M.; Krauss S.; Scholz H.; Wilson S. R. Simultaneous LC-MS determination of glucose regulatory peptides secreted by stem cell-derived islet organoids. Electrophoresis 2023, 44, 1682–1697. 10.1002/elps.202300095. PubMed DOI
Kogler S.; Aizenshtadt A.; Harrison S.; Skottvoll F. S.; Berg H. E.; Abadpour S.; Scholz H.; Sullivan G.; Thiede B.; Lundanes E.; Bogen I. L.; Krauss S.; Røberg-Larsen H.; Wilson S. R. Organ-in-a-Column” Coupled On-line with Liquid Chromatography-Mass Spectrometry. Anal. Chem. 2022, 94, 17677–17684. 10.1021/acs.analchem.2c04530. PubMed DOI PMC
Hrušková H.; Olsen C.; Řemínek R.; Wang C.; Aizenshtadt A.; Krauss S.; Scholz H.; Røberg-Larsen H.; Foret F.; Wilson S. R. Preparative agarose gel electrophoresis for reducing matrix interferences of organoid cell medium prior to LC-MS analysis of insulin. J. Chromatogr. A 2024, 1717, 464669.10.1016/j.chroma.2024.464669. PubMed DOI
Skottvoll F. S.; Aizenshtadt A.; Hansen F. A.; Martinez M. A.; Andersen J. M.; Bogen I. L.; Kutter J. P.; Pedersen-Bjergaard S.; Lundanes E.; Krauss S.; Wilson S. R. Direct Electromembrane Extraction-Based Mass Spectrometry: A Tool for Studying Drug Metabolism Properties of Liver Organoids. Analysis Sensing 2022, 2, e20210005110.1002/anse.202100051. DOI
Svendsen K. O.; Larsen H. R.; Pedersen S. A.; Brenna I.; Lundanes E.; Wilson S. R. Automatic filtration and filter flush for robust online solid-phase extraction liquid chromatography. J. Sep. Sci. 2011, 34, 3020–3022. 10.1002/jssc.201100553. PubMed DOI
Kømurcu K. S.; Wilhelmsen I.; Thorne J. L.; Krauss S.; Wilson S. R.; Aizenshtadt A.; Røberg-Larsen H. Mass spectrometry reveals that oxysterols are secreted from non-alcoholic fatty liver disease induced organoids. J. Steroid Biochem. Mol. Biol. 2023, 232, 106355.10.1016/j.jsbmb.2023.106355. PubMed DOI
LaLone V.; Aizenshtadt A.; Goertz J.; Skottvoll F. S.; Mota M. B.; You J.; Zhao X.; Berg H. E.; Stokowiec J.; Yu M.; Schwendeman A.; Scholz H.; Wilson S. R.; Krauss S.; Stevens M. M. Quantitative chemometric phenotyping of three-dimensional liver organoids by Raman spectral imaging. Cells Rep. Methods 2023, 3, 100440.10.1016/j.crmeth.2023.100440. PubMed DOI PMC
Busek M.; Aizenshtadt A.; Koch T.; Frank A.; Delon L.; Martinez M. A.; Golovin A.; Dumas C.; Stokowiec J.; Gruenzner S.; Melum E.; Krauss S. Pump-less, recirculating organ-on-a-chip (rOoC) platform. Lab Chip 2023, 23, 591–608. 10.1039/d2lc00919f. PubMed DOI
FDA’s Guidelines for Bioanalytical Method Validation. https://www.fda.gov/media/70858/download.
Abadpour S.; Niemi E. M.; Orrhult L. S.; Hermanns C.; de Vries R.; Nogueira L. P.; Haugen H. J.; Josefsen D.; Krauss S.; Gatenholm P.; et al. Adipose-Derived Stromal Cells Preserve Pancreatic Islet Function in a Transplantable 3D Bioprinted Scaffold. Adv. Healthcare Mater. 2023, 12, 2300640.10.1002/adhm.202300640. PubMed DOI PMC
The Fitness for Purpose of Analytical Methods A Laboratory Guide to Method Validation and Related Topics by EuChem, n.d. EuChem webpage. https://www.eurachem.org/images/stories/Guides/pdf/MV_guide_2nd_ed_EN.pdf.